You searched for: cereno scientific
Cereno Scientific on the financing solution
Cereno Scientific today announced a comprehensive financing solution that strengthens the company in the execution of the global Phase IIb study with CS1...
Cereno Scientific receives SEK 4 million through the exercise of warrants
Cereno Scientific takes the next step towards phase IIb study in PAH
Cereno Scientific has submitted the study protocol for its planned global Phase IIb study with the drug candidate CS1 to the US Food and Drug Administration...
Cereno Scientific submits protocol for Phase IIb study to FDA
Q2 report shows progress for Cereno Scientific's pipeline and strategy
Cereno Scientific's second quarter of 2025 was marked by clinical progress, regulatory milestones and a strengthened financial position. The company is lifting...
Cereno Scientific receives FDA Fast Track for PAH treatment
The US Food and Drug Administration (FDA) has granted Fast Track status to CS1 for the treatment of pulmonary arterial hypertension, a rare and...
Cereno Scientific reports positive Phase I results
Cereno Scientific signs agreement with CRO for phase IIb study
Cereno Scientific has taken an important step towards the start of the Phase IIb study for the drug candidate CS1 by signing an agreement...
Cereno Scientific selects CRO for Phase IIb study
Cereno Scientific communicates Phase I results in July
Cereno Scientific secures SEK 100 million in financing
Promising 4-month data from Cereno's Expanded Access Program
Cereno Scientific has announced 4-month follow-up data from its Expanded Access Program for the drug candidate CS1. The results are in line with...
Cereno Scientific advances on a broad front during Q1
Cereno Scientific's first quarter report shows continued progress. During the period, progress has been made in both CS1 and...
Cereno Scientific in agreement with FDA on the development of CS1
Cereno Scientific has taken another important step forward with the drug candidate CS1. Yesterday, the Swedish biotechnology company held a...
Cereno's CS014 study on target aiming for topline data in June
Cereno Scientific announced today that the second and final part of the company's Phase I study with the drug candidate CS014 in healthy...
Additional data strengthens Cereno's CS1 in PAH
Following promising Phase IIa results for the drug candidate CS1 against pulmonary arterial hypertension (PAH) in October 2024, Cereno Scientific is now delivering...
Cereno Scientific to evaluate CS1 with advanced imaging technology
Cereno Scientific announces that a substudy with CS1 within the ongoing Extended Access Program (EAP) can now be initiated after...
Cereno Scientific's HDAC inhibitor CS014 advances
Cereno Scientific, which develops treatments for rare cardiovascular and lung diseases, announces that the first part of the Phase I study...
Significant third quarter for Cereno
Cereno Scientific delivered a strong Q3 2024, not least through positive Phase IIa results for the lead candidate CS1. With several important...
Another successful Summit – see all videos here
On November 20-21, we invited you to the BioStock Life Science Summit for the seventh time and now you can see...
What does Cereno Scientific's loan of SEK 250 million mean for shareholders?
Following the positive results from the company's Phase II study and the announcement that it is choosing to focus entirely on rare diseases,...
Cereno Scientific CEO on new treatments for rare diseases
BioStock met with Cereno Scientific CEO Sten R. Sörensen at BioEurope. Cereno Scientific is developing new treatments for rare diseases in...
BioStock meets industry experts at BIO-Europe
The BIO-Europe partnering event has been an important hub for life science industry players, both for knowledge exchange and networking, for three decades....
The temperature at Cereno Scientific after significant news
Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014....